MedWatch

Bank identifies rising costs for Lundbeck, lowers share price target

Lundbeck’s R&D expenses are going up as key patent expiration dates draw nearer – but no obvious candidates are ready to take up the mantle.

Photo: Lundbeck / PR

An analysis from Swedish bank Handelsbanken points to several positive developments in terms of Lundbeck’s pipeline but also notes increasing costs for the pharmaceutical firm.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs